Patents by Inventor Neil INHABER

Neil INHABER has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230174674
    Abstract: Provided herein are methods for treating acute respiratory distress syndrome (ARDS), such as ARDS associated with respiratory virus infection, involving administering an inhibitor of the contact activation pathway. Also provided herein are methods for treating pneumonia and methods for reducing and/or preventing thrombosis associated with extracorporeal membrane oxygenation (ECMO) in a subject having acute respiratory distress syndrome (ARDS), involving administering an inhibitor of the contact activation pathway.
    Type: Application
    Filed: April 2, 2021
    Publication date: June 8, 2023
    Applicant: Takeda Pharmaceutical Company Limited
    Inventors: Daniel J. Sexton, Neil Inhaber, Giorgio Giannattasio, Donatello Crocetta
  • Patent number: 11602583
    Abstract: A Direct Sodium Removal method, apparatus and solution for treating patients in heart failure, and having a glomerular filtration rate greater than 15 mL/min/1.73 m2, or residual kidney function corresponding to normal to CKD Stage 4, is provided in which a no or low sodium DSR infusate is administered to the peritoneal cavity for a predetermined dwell period and then removed, thereby removing sodium from the body. The resulting elimination of fluid from the patient by i) functioning of the kidneys through urination and ii) direct removal of osmotic ultrafiltrate from the peritoneal cavity, restores serum sodium concentrations to healthy levels and thereby reduces fluid overload in the patient.
    Type: Grant
    Filed: February 12, 2021
    Date of Patent: March 14, 2023
    Assignee: Sequana Medical NV
    Inventors: Neil Inhaber, Noel Johnson, Dirk Fengels, Ian Crosbie
  • Publication number: 20210187179
    Abstract: A Direct Sodium Removal method, apparatus and solution for treating patients in heart failure, and having a glomerular filtration rate greater than 15 mL/min/1.73 m2, or residual kidney function corresponding to normal to CKD Stage 4, is provided in which a no or low sodium DSR infusate is administered to the peritoneal cavity for a predetermined dwell period and then removed, thereby removing sodium from the body. The resulting elimination of fluid from the patient by i) functioning of the kidneys through urination and ii) direct removal of osmotic ultrafiltrate from the peritoneal cavity, restores serum sodium concentrations to healthy levels and thereby reduces fluid overload in the patient.
    Type: Application
    Filed: February 12, 2021
    Publication date: June 24, 2021
    Applicant: Sequana Medical NV
    Inventors: Neil INHABER, Noel JOHNSON, Dirk FENGELS, Ian CROSBIE
  • Patent number: 10918778
    Abstract: A Direct Sodium Removal method, apparatus and solution for treating patients in heart failure, and having a glomerular filtration rate greater than 15 mL/min/1.73 m2, or residual kidney function corresponding to normal to CKD Stage 4, is provided in which a no or low sodium DSR infusate is administered to the peritoneal cavity for a predetermined dwell period and then removed, thereby removing sodium from the body. The resulting elimination of fluid from the patient by i) functioning of the kidneys through urination and ii) direct removal of osmotic ultrafiltrate from the peritoneal cavity, restores serum sodium concentrations to healthy levels and thereby reduces fluid overload in the patient.
    Type: Grant
    Filed: May 21, 2018
    Date of Patent: February 16, 2021
    Assignee: Sequana Medical NV
    Inventors: Neil Inhaber, Noel Johnson, Dirk Fengels, Ian Crosbie
  • Patent number: 10898631
    Abstract: A Direct Sodium Removal method, apparatus and solution for treating patients in heart failure, and having a glomerular filtration rate greater than 15 mL/min/1.73 m2, or residual kidney function corresponding to normal to CKD Stage 4, is provided in which a no or low sodium DSR infusate is administered to the peritoneal cavity for a predetermined dwell period and then removed, thereby removing sodium from the body. The resulting elimination of fluid from the patient by i) functioning of the kidneys through urination and ii) direct removal of osmotic ultrafiltrate from the peritoneal cavity, restores serum sodium concentrations to healthy levels and thereby reduces fluid overload in the patient.
    Type: Grant
    Filed: May 21, 2018
    Date of Patent: January 26, 2021
    Assignee: Sequana Medical NV
    Inventors: Neil Inhaber, Noel Johnson, Dirk Fengels, Ian Crosbie
  • Publication number: 20180344917
    Abstract: A Direct Sodium Removal method, apparatus and solution for treating patients in heart failure, and having a glomerular filtration rate greater than 15 mL/min/1.73 m2, or residual kidney function corresponding to normal to CKD Stage 4, is provided in which a no or low sodium DSR infusate is administered to the peritoneal cavity for a predetermined dwell period and then removed, thereby removing sodium from the body. The resulting elimination of fluid from the patient by i) functioning of the kidneys through urination and ii) direct removal of osmotic ultrafiltrate from the peritoneal cavity, restores serum sodium concentrations to healthy levels and thereby reduces fluid overload in the patient.
    Type: Application
    Filed: May 21, 2018
    Publication date: December 6, 2018
    Applicant: Sequana Medical AG
    Inventors: Neil INHABER, Noel JOHNSON, Dirk FENGELS, Ian CROSBIE
  • Publication number: 20180338914
    Abstract: A Direct Sodium Removal method, apparatus and solution for treating patients in heart failure, and having a glomerular filtration rate greater than 15 mL/min/1.73 m2, or residual kidney function corresponding to normal to CKD Stage 4, is provided in which a no or low sodium DSR infusate is administered to the peritoneal cavity for a predetermined dwell period and then removed, thereby removing sodium from the body. The resulting elimination of fluid from the patient by i) functioning of the kidneys through urination and ii) direct removal of osmotic ultrafiltrate from the peritoneal cavity, restores serum sodium concentrations to healthy levels and thereby reduces fluid overload in the patient.
    Type: Application
    Filed: May 21, 2018
    Publication date: November 29, 2018
    Applicant: Sequana Medical AG
    Inventors: Neil INHABER, Noel JOHNSON, Dirk FENGELS, Ian CROSBIE